Histopathological assessment of the intensity and activity of the inflammation in inflammatory bowel diseases: An important addition to the endoscopy, or a pointless effort?
Authors:
Ondřej Fabián 1; Ondřej Hradský 2; Jiří Bronský 2; Josef Zámečník 1
Authors place of work:
Ústav patologie a molekulární medicíny 2. LF UK a FN Motol, Praha
1; Pediatrická klinika 2. LF UK a FN Motol, Praha
2
Published in the journal:
Čes.-slov. Patol., 55, 2019, No. 3, p. 158-164
Category:
Summary
Expanding amount of knowledge about inflammatory bowel diseases has changed current therapeutic goals. In the past times, the main effort of the gastroenterologists was to alleviate patients’ symptoms. But nowadays, one of the hot topics is a mucosal healing and achieving the endoscopic, eventually even microscopic remission. Therefore, the objective assessment of the microscopic intensity and activity of the inflammation starts to assume its importance and histopathological scoring systems can represent an useful tool. However, their actual contribution is ill-defined.
The aim of this review is to inform about available histopathological scoring systems for ulcerative colitis (UC) and Crohn’s disease (CD) and discuss their benefits and limitations. A systematic literature search in databases OVID SP MEDLINE, OVID EMBASE a The Cochrane library found 19 scoring indexes for UC and 4 for CD were found. The vast majority of them are not validated and their benefit for prediction of the clinical outcome is controversial. Endoscopy still represents a gold standard in the assessment of the extent of the bowel inflammation.
Keywords:
Ulcerative colitis – inflammatory bowel disease – histopathology – scoring index
Zdroje
1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional Ileitis: A Pathologic and Clinical Entity. JAMA 1932; 99(16): 1323-1329.
2. Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis 2017; 11(6): 649-670.
3. Gomollón F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis 2017; 11(1): 3-25.
4. Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013; 7(10): 827-851.
5. Travis SP, Higgins PD, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 34(2): 113-124.
6. Daperno M, Castiglione F, de Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011; 5(5): 484-498.
7. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5(5): 477-483.
8. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 2006; 55(Suppl 1): i1-i15.
9. Reinisch W, Van Assche G, Befrits R, et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis 2012; 6(2): 248-258.
10. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9(6): 483-189.
11. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population based cohort. Gastroenterology 2007; 133(2): 412-422.
12. Korelitz BI. Mucosal healing as an index of colitis activity: back to histological healing for future indices. Inflamm Bowel Dis 2010; 16(9): 1628-1630.
13. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32(2): 174-178.
14. Rosenberg L, Nanda KS, Zenlea T, et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol 2013; 11(8): 991-996.
15. Molander P, Sipponen T, Kemppainen H, et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha-blocking agents in IBD. J Crohns Colitis 2013; 7(9): 730-735.
16. Korelitz BI, Sommers SC. Response to drug therapy in Crohn’s disease: evaluation by rectal biopsy and mucosal cell counts. J Clin Gastroenterol 1984; 6(2): 123-127.
17. Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014; 8(12): 1582-1597.
18. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J 1956; 1(4979): 1315-1318.
19. Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med 1961; 30: 393-407.
20. Watts JM, Thompson H, Goligher JC. Sigmoidoscopy and cytology in the detection of microscopic disease of the rectal mucosa in ulcerative colitis. Gut 1966; 7(3): 288-294.
21. Powell-Tuck J, Day DW, Buckell NA, et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27(6): 533-537.
22. Keren DF, Appelman HD, Dobbins III WO, et al. Correlation of histopathologic evidence of disease activity with the presence of immunoglobulin-containing cells in the colons of patients with inflammatory bowel disease. Hum Pathol 1984; 15(8): 757-763.
23. Friedman LS, Richter JM, Kirkham SE, et al. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am J Gastroenterol 1986; 81(6): 412-418.
24. Gomes P, du Boulay C, Smith CL, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27(1): 92-95.
25. Saverymuttu SH, Camilleri M, Rees H, et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986; 90(5 Pt 1): 1121-1128.
26. Floren CH, Benoni C, Willen R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 1987; 22(4): 459-462.
27. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88(8): 1188-1197.
28. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993; 88(5): 640-645.
29. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47(3): 404-409.
30. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126(2): 451-459.
31. Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012; 18(9): 1634-1640.
32. D’Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114(2): 262-267.
33. Nicholls S, Domizio P, Williams CB, et al. Cyclosporin as initial treatment for Crohn’s disease. Arch Dis Child 1994; 71(3): 243-247.
34. Breese EJ, Michie CA, Nicholls SW, et al. The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn’s disease. Aliment Pharmacol Ther 1995; 9(5): 547-552.
35. Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012; 18(9): 1634-1640.
36. Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. Gut 2017; 66(1): 43-49.
37. Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut 2017; 66(1): 50-58.
38. Jauregui-Amezaga A, Geerits A, Das Y, et al. A Simplified Geboes Score for Ulcerative Colitis. J Crohns Colitis 2017; 11(3): 305-313.
39. Bessho R, Kanai T, Hosoe N, et al. Correlation between endocytoscopy and conventional histopathology in microstructural features of ulcerative colitis. J Gastroenterol 2011; 46(10): 1197-1202.
40. Lemmens B, Arijs I, Van Assche G, et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis 2013; 19(6): 1194-1201.
41. Fluxa D, Simian D, Flores L, et al. Clinical, endoscopic and histological correlation and measures of association in ulcerative colitis. J Dig Dis 2017; 18(11): 634-641.
42. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317(26): 1625-1629.
43. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966; 11(11): 847-857.
44. Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol 2011; 17(3): 194-198.
45. Zenlea T, Yee EU, Rosenberg L, et al. Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. Am J Gastroenterol 2016; 111(5): 685-690.
46. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120(1): 13-20.
47. Hefti MM, Chessin DB, Harpaz NH, et al. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum 2009; 52(2): 193-197.
48. Burger DC, Thomas SJ, Walsh AJ, et al. Depth of remission may not predict outcome of UC over 2 years. J Crohns Colitis 2011; 5(S3): S4-5.
49. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012; 107(11): 1684-1692.
50. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133(4): 1099-1105.
51. Irani NR, Wang LM, Collins GS. Correlation between Endoscopic and Histological Activity in Ulcerative Colitis using Validated Indices. J Crohns Colitis 2018; in press.
52. Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013; 145(5): 987-995.
53. D’Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999; 116(5): 1029-1034.
54. Geboes K, Rutgeerts P, Opdenakker G, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn’s disease. Curr Med Res Opin 2005; 21(11): 1741-1754.
55. Noble A, Turner D. Clinical indices for pediatric inflammatory bowel disease research. In: Mamula P, Markowitz JE, Baldassano RN, eds. Pediatric Inflammatory Bowel Disease (1st ed). New York, NY: Springer; 2008: 507-530.
56. Ashton JJ, Coelho T, Ennis S, Vadgama B, Batra A, Afzal NA, Beattie RM. Endoscopic Versus Histological Disease Extent at Presentation of Paediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2016; 62(2): 246-251.
57. Fernandes MA, Verstraete SG, Garnett EA, Heyman MB. Addition of Histology to the Paris Classification of Pediatric Crohn Disease Alters Classification of Disease Location. J Pediatr Gastroenterol Nutr 2016; 62(2): 242-245.
58. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17(6): 1314-1321.
59. Fabián O, Hradský O, Potužníková K, et al. Low predictive value of histopathological scoring system for complications development in children with Crohn’s disease. Pathol Res Pract 2017; 213(4): 353-358.
60. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004; 60(4): 505-512.
61. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 1991; 12(4): 439-447.
62. Mosli MH, Parker CE, Nelson SA, et al. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2017; 5: CD011256.
63. Novak G, Parker CE, Pai RK, et al. Histologic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database Syst Rev 2017; 7: CD012351.
64. D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132(2): 763-786.
65. D’Haens GR, Fedorak R, Lemann M,et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn’s disease. Inflamm Bowel Dis 2009; 15(10): 1599-1604.
66. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2014; 12(6): 929-934.
67. Villanacci V, Antonelli E, Geboes K, et al. Histological healing in inflammatory bowel disease: a still unfulfilled promise. World J Gastroenterol 2013; 19(7): 968-978.
68. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014; 58(6): 795-806.
69. Gralnek IM, Defranchis R, Seidman E, Leighton JA, Legnani P, Lewis BS. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 2008; 27(2): 146-154.
70. Gal E, Geller A, Fraser G, Levi Z, Niv Y. Assessment and validation of the new capsule endoscopy Crohn’s disease activity index (CECDAI). Dig Dis Sci 2008; 53(7): 1933-1937.
71. Ferrante M, de Hertogh G, Hlavaty T, et al. The value of myenteric plexitis to predict early postoperative Crohn’s disease recurrence. Gastroenterology 2006; 130(6): 1595-1606.
72. Pariente B, Mary JY, Danese S, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology 2015; 148(1): 52-63.
73. Fabián O, Hradský O, Dršková T, Mikuš F, Zámečník J, Bronský J. Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis. Dig Dis Sci 2018; 63(7): 1811-1818.
74. Cuffari C. Diagnostic considerations in pediatric inflammatory bowel disease management. Gastroenterol Hepatol 2009; 11: 775-783.
75. Winter DA, Karolewska-Bochenek K, Lazowska-Przeorek I, et al. Pediatric IBD-unclassified Is Less Common than Previously Reported; Results of an 8-Year Audit of the EUROKIDS Registry. Inflamm Bowel Dis 2015; 21(9): 2145-2153.
76. Martin-de-Carpi J, Rodriguez A, Ramos E, et al. The complete picture of changing pediatric inflammatory bowel disease incidence in Spain in 25 years
Štítky
Anatomical pathology Forensic medical examiner ToxicologyČlánok vyšiel v časopise
Czecho-Slovak Pathology
2019 Číslo 3
Najčítanejšie v tomto čísle
- Cytological examination of cerebrospinal fluid
- Neuronal ceroid lipofuscinosis with cardiac involvement
- Pituitary adenomas – practical approach to the diagnosis and the changes in the 2017 WHO classification
- Metanephric adenoma. A case report and literature review